Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2013 Jul 25;13(3):181–192. doi: 10.3233/CBM-130337

Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity

Zezhong Li a,c,1, Xin He b,1, Shenyang Xing a,c, Jinsong Ni b, Weihong Zhang b, Xiaofang Xu a, Feng Gao a,c, Jinhong Gai a, Zhihui Zhao a,c, Jianhua Li a, Pengtao Gong a, Guocai Zhang a, Xichen Zhang a,*
Editors: Amal Melhem-Bertrandtx, Anil K Soody
PMCID: PMC12928270  PMID: 23912490

Abstract

Background:

Ductal carcinoma in situ of the breast constitutes the early stage of breast cancer when cancer cells are confined by the intact myoepithelial cell layer. Transition from DCIS to invasive carcinoma is a process yet poorly understood.

Materials and Methods:

By liquid chromatography (LC) and mass spectrometry (MS/MS) methods, we analyzed this early event using paired samples of micro-dissected cells overlaid with focally disrupted myoepithelial layers and their adjacent counterparts within the intact duct from formalin-fixed paraffin-embedded blocks.

Results:

AKR1B10, a member of Aldo-keto reductase family, was shown to be abundantly located in the filtering cells among a catalog of proteins. Moreover, strong correlation between AKR1B10 and HER2 positivity was found in an independent cohort of DCIS samples.

Conclusion:

AKR1B10 could become a potential diagnosis and therapeutic marker for early breast cancers with HER2 overexpression and poor prognosis.

Keywords: AKR1B10, HER2, correlation, DCIS

Full Text

The Full Text of this article is available as a PDF (1.8 MB).

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES